{"ok":true,"entity":{"id":"genmab","name":"Genmab","entityType":"company","officialName":"Genmab A/S","canonicalName":"Genmab","displayName":"Genmab","category":"抗体医薬のバイオテクノロジー企業","shortDescription":"Genmab A/Sは、デンマークのValby（コペンハーゲン）に主たる事務所を置く抗体医薬のバイオテクノロジー企業で、Nasdaqにも上場（GMAB）。2026年上半期の売上高は20億5,100万米ドル、営業利益は5億5,500万米ドル。2025年12月12日にMerusの買収を完了し（同社の中間報告書による）、2025年11月にはFDAがepcoritamab-bysp（Epkinly）の濾胞性リンパ腫適応を承認した。","primaryCluster":"biotech-genomics","parentEntity":null,"verificationStatus":"draft","website":"https://www.genmab.com/","updatedAt":"2026-10-22T11:50:32.298Z","secondaryClusters":[],"alias":["Genmab A/S"],"searchKeywords":["Genmab","ゲンマブ","抗体医薬","epcoritamab","エプキンリ","Merus買収","GMAB","bispecific antibody"]},"referenceIndex":["P-01-001","P-02-001","P-04-001","P-05-001","P-06-001"]}